What is INO stock price today?

INO (Inovio Pharmaceuticals Inc) stock is trading at $1.19 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is INO stock going up or down today?

INO stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy INO stock now?

The decision to buy INO depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is INO a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for INO based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is INO stock overvalued or undervalued?

Use our DCF valuation calculator to determine if INO is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is INO's P/E ratio?

P/E ratio data for INO will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is INO's market cap?

INO (Inovio Pharmaceuticals Inc) has a market capitalization of $0.09 billion, making it a small-cap stock.

What is INO's price to book ratio?

INO trades at a price-to-book (P/B) ratio of 3.69, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does INO pay dividends?

INO does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is INO's dividend yield?

INO does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is INO stock a good long-term investment?

INO's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is INO's revenue growth rate?

INO has shown revenue growth of -1.0% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

Profitability metrics for INO are available on our dashboard with complete income statement analysis.

What are the risks of investing in INO?

Key risks for INO include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does INO compare to its competitors?

Compare INO to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize INO's performance and positioning.

What is INO's stock price target for 2026?

Our AI model provides price targets for INO based on fundamental analysis: Bull case $1.55 (+30%), Base case $1.37 (+15%), Bear case $1.07 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about INO?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for INO. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is INO's next earnings report?

INO reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

INO - Inovio Pharmaceuticals Inc

NYSE * Health Care * Biotechnology

$1.19

+$0.08 (+7.21%)

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company's lead product candidate is INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade squamous intraepithelial lesions; INO-3112 for the treatment of HPV-related Oropharyngeal squamous cell carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 2/3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. The company's partners and collaborators ApolloBio Corporation, AstraZeneca, Coherus Biosciences, Defense Advanced Research Projects Agency, HIV Vaccines Trial Network, Kaneka Eurogentec, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter BioLogics, the University of Pennsylvania, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

INO Key Statistics

Market Cap

$90.57M

P/B Ratio

3.69

EPS

$-1.81

Revenue Growth

-1.0%

Employees

112

How INO Compares to Peers

INO is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

N/A

of 5

Growth Rank

of 6

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
INO(This stock)	$90.57M	N/A	-1%	0.0%	-
AMGNAmgen Inc	$189.19B	24.7	0%	0.2%	vs AMGN
GILDGilead Sciences	$174.33B	20.7	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$113.01B	29.0	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$79.87B	18.2	0%	0.3%	vs REGN
BIIBBiogen Inc	$26.50B	20.5	-0%	0.1%	vs BIIB

Inovio Pharmaceuticals Inc Company Information

Headquarters: California; U.S.A
Website: www.inovio.com
Sector: Health Care
Industry: Biotechnology

INO - Inovio Pharmaceuticals Inc

About Inovio Pharmaceuticals Inc

INO Key Statistics

How INO Compares to Peers

Inovio Pharmaceuticals Inc Company Information

INO Lician Score

INO Financial Snowflake

Upcoming Events for INO